These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30830371)

  • 1. Metabolomics approach for predicting response to neoadjuvant chemotherapy for colorectal cancer.
    Yang K; Zhang F; Han P; Wang ZZ; Deng K; Zhang YY; Zhao WW; Song W; Cai YQ; Li K; Cui BB; Zhu ZJ
    Metabolomics; 2018 Aug; 14(9):110. PubMed ID: 30830371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A metabolomics approach for predicting the response to neoadjuvant chemotherapy in cervical cancer patients.
    Hou Y; Yin M; Sun F; Zhang T; Zhou X; Li H; Zheng J; Chen X; Li C; Ning X; Lou G; Li K
    Mol Biosyst; 2014 Aug; 10(8):2126-33. PubMed ID: 24865370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer.
    Wei S; Liu L; Zhang J; Bowers J; Gowda GA; Seeger H; Fehm T; Neubauer HJ; Vogel U; Clare SE; Raftery D
    Mol Oncol; 2013 Jun; 7(3):297-307. PubMed ID: 23142658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting dynamic response to neoadjuvant chemotherapy in breast cancer: a novel metabolomics approach.
    Díaz C; González-Olmedo C; Díaz-Beltrán L; Camacho J; Mena García P; Martín-Blázquez A; Fernández-Navarro M; Ortega-Granados AL; Gálvez-Montosa F; Marchal JA; Vicente F; Pérez Del Palacio J; Sánchez-Rovira P
    Mol Oncol; 2022 Jul; 16(14):2658-2671. PubMed ID: 35338693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UHPLC-HRMS-based Multiomics to Explore the Potential Mechanisms and Biomarkers for Colorectal Cancer.
    Wang X; Guan X; Tong Y; Liang Y; Huang Z; Wen M; Luo J; Chen H; Yang S; She Z; Wei Z; Zhou Y; Qi Y; Zhu P; Nong Y; Zhang Q
    BMC Cancer; 2024 May; 24(1):644. PubMed ID: 38802800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive analysis of breast cancer response to neoadjuvant chemotherapy through plasma metabolomics.
    Yamada M; Jinno H; Naruse S; Isono Y; Maeda Y; Sato A; Matsumoto A; Ikeda T; Sugimoto M
    Breast Cancer Res Treat; 2024 Sep; 207(2):393-404. PubMed ID: 38740665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Graf A; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Ann Surg Oncol; 2015 Apr; 22(4):1315-23. PubMed ID: 25323471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A quantitative multimodal metabolomic assay for colorectal cancer.
    Farshidfar F; Kopciuk KA; Hilsden R; McGregor SE; Mazurak VC; Buie WD; MacLean A; Vogel HJ; Bathe OF
    BMC Cancer; 2018 Jan; 18(1):26. PubMed ID: 29301511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted serum metabolite profiling and sequential metabolite ratio analysis for colorectal cancer progression monitoring.
    Zhu J; Djukovic D; Deng L; Gu H; Himmati F; Abu Zaid M; Chiorean EG; Raftery D
    Anal Bioanal Chem; 2015 Oct; 407(26):7857-63. PubMed ID: 26342311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization of the 21-Gene Recurrence Score in a Diverse Breast Cancer Patient Population: Development of a Clinicopathologic Model to Predict High-Risk Scores and Response to Neoadjuvant Chemotherapy.
    Park KU; Chen Y; Chitale D; Choi S; Ali H; Nathanson SD; Bensenhaver J; Proctor E; Petersen L; Loutfi R; Simonds A; Kuklinski M; Doyle T; Dabak V; Cole K; Davis M; Newman L
    Ann Surg Oncol; 2018 Jul; 25(7):1921-1927. PubMed ID: 29679201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Correlative Strategy To Discover Colorectal Tumor Tissue Derived Metabolite Biomarkers in Plasma Using Untargeted Metabolomics.
    Wang Z; Cui B; Zhang F; Yang Y; Shen X; Li Z; Zhao W; Zhang Y; Deng K; Rong Z; Yang K; Yu X; Li K; Han P; Zhu ZJ
    Anal Chem; 2019 Feb; 91(3):2401-2408. PubMed ID: 30580524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer.
    Jain P; Doval DC; Batra U; Goyal P; Bothra SJ; Agarwal C; Choudhary DK; Yadav A; Koyalla VPB; Sharma M; Dash P; Talwar V
    Jpn J Clin Oncol; 2019 Apr; 49(4):329-338. PubMed ID: 30753543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct urinary metabolic profile of human colorectal cancer.
    Cheng Y; Xie G; Chen T; Qiu Y; Zou X; Zheng M; Tan B; Feng B; Dong T; He P; Zhao L; Zhao A; Xu LX; Zhang Y; Jia W
    J Proteome Res; 2012 Feb; 11(2):1354-63. PubMed ID: 22148915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultra‑performance liquid chromatography coupled with quadrupole time‑of‑flight mass spectrometry‑based metabolic profiling of human serum prior to and following radical resection of colorectal carcinoma.
    Chen L; Zhang C; Gui Q; Chen Y; Yang Y
    Mol Med Rep; 2015 Nov; 12(5):6879-86. PubMed ID: 26352758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiological and Pathological Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Brief Literature Review.
    Parekh T; Dodwell D; Sharma N; Shaaban AM
    Pathobiology; 2015 Sep; 82(3-4):124-32. PubMed ID: 26330353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
    Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
    Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic phenotyping to monitor chronic enteritis canceration.
    Zhang F; Li C; Deng K; Wang Z; Zhao W; Yang K; Yang C; Rong Z; Cao L; Lu Y; Huang Y; Han P; Li K
    Metabolomics; 2020 Feb; 16(3):29. PubMed ID: 32095917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics.
    Farshidfar F; Weljie AM; Kopciuk KA; Hilsden R; McGregor SE; Buie WD; MacLean A; Vogel HJ; Bathe OF
    Br J Cancer; 2016 Sep; 115(7):848-57. PubMed ID: 27560555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of differential metabolic characteristics between tumor and normal tissue from colorectal cancer patients by gas chromatography-mass spectrometry.
    Ning W; Li H; Meng F; Cheng J; Song X; Zhang G; Wang W; Wu S; Fang J; Ma K; Yang J; Pei D; Dong F
    Biomed Chromatogr; 2017 Nov; 31(11):. PubMed ID: 28475217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple-matrix metabolomics analysis for the distinct detection of colorectal cancer and adenoma.
    Zhang Y; Ni M; Tao Y; Shen M; Xu W; Fan M; Shan J; Cheng H
    Metabolomics; 2024 Apr; 20(3):47. PubMed ID: 38642214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.